The prevalence of Group I PAH is 15–26 cases/million (Archer et al., 2010) and ACVRL1 mutations constitute approximately 1% of cases (Machado et al., 2015), so ACVRL1 mutations are most frequently causal of HHT. Here, ACVRL1 is linked to pulmonary arterial hypertension.